Registration for the HTRS 2021 Scientific Symposium
HTRS 2021 is a comprehensive scientific meeting dedicated to the advancement of continuing medical education and research related to bleeding and thrombotic disorders in both pediatric and adult medicine. The Symposium will be held virtually Wednesday, March 10, 2021 through Friday, March 12, 2021.

HTRS anticipates an audience of 700+ virtual attendees, including physicians, nurses, pharmacists, residents and fellows, coagulation laboratory technicians, and other allied healthcare professionals from the U.S., Canada, and abroad dedicated to the diagnosis, management, and research of bleeding and thrombotic disorders.

Registration Rates:

Registration Category

Early Bird Rate

(on or before 01/15/21)

Regular Rate

(after 01/15/21)

HTRS Core Member - MD/DO/PhD

$ 150.00

$ 175.00

HTRS Associate Member - Nurses/Pharmacists/or other Healthcare Professionals

$ 85.00

$ 110.00

HTRS Trainee or Student Member - Resident/Fellows/Post-Docs/Medical Students/PhD Candidates

$ 50.00

$ 75.00

HTRS Industry Members (Corporate Colleagues)

$ 325.00

$ 400.00

Non-HTRS Member MD/DO/PhDs

$ 225.00

$ 250.00

Non-Member - Nurses/Pharmacists/or other Healthcare Professionals

$ 100.00

$ 125.00

Non-Member - Resident/Fellows/Post-Docs/Medical Students/PhD Candidates

$ 75.00

$ 100.00

Non-Member Industry Professionals 

$ 550.00

$ 600.00


Pre-Conference Events

HTRS Research Colloquium
Registration is still open! Junior faculty and early-stage investigators (MDs, DOs, MD/PhDs, and PhDs) are encouraged to attend the live, online event March 8-9, 2021. Interested participants can now register for the Colloquium via the separate registration portal.

What to Expect: This dynamic meeting was originally designed to provide in-person professional education and promote career development.  This will still be the case, though all will happen in a professionally designed virtual environment. Attendees will exchange ideas, establish or renew professional relationships, attend challenging scientific sessions and breakout sessions, and discuss the latest research in hemostasis and thrombosis.  There will be a focus on networking and mentoring; participants will enjoy plenty of time to connect with peers and expert mentors dedicated to bridging the traditional "bench to bedside gap" to improve the lives of patients with disorders of hemostasis and thrombosis.

Click here to register to attend the Research Colloquium.

HTRS Multidisciplinary Workshop
All healthcare providers are encouraged to register for the Multi-Disciplinary Pre-Conference. A diverse lineup of healthcare providers will present the latest advances in treating patients with hemostatic and thrombotic disorders. Session 1, “New Therapies,” takes place 10:00 AM – 11:30 AM ET on Wednesday, March 10. Session 2, “Inclusive Care,” takes place 10:00 AM – 11:30 AM ET on Thursday, March 11. The Multi-Disciplinary Pre-Conference is a certified Continuing Education / Continuing Medical Education activity.

Registration Category

Early Bird Rate

(on or before 01/15/21)

Regular Rate

(after 01/15/21)

Multidisciplinary Pre-Conference



Click Here for the full meeting agenda. Register for this event through the HTRS registration portal.

FWGBD Colloquium on Uterine Hemostasis
The Foundation for Women & Girls with Blood Disorders (FWGBD - biennial colloquium on uterine hemostasis, scheduled for March 9, 2021 from 9:00 AM ET - 12:30 PM ET, will convene leading faculty/researchers/clinicians to review our current understanding of the science and evidence-based practice related to the diagnosis and clinical management of abnormal uterine hemostasis.

The Proposed Meeting Objectives and Goals:

  • Convene top experts in the fields of Obstetrics/Gynecology and in Hematology, who are working in uterine hemostasis and blood disorders in women and girls.
  • Review the state of the science with respect to normal uterine hemostasis.
  • Recognize the range of complications related to abnormal uterine hemostasis.
  • Describe and review the epidemiology and variability in phenotype regarding women with hemophilia.
  • Examine the full range of options for achieving uterine hemostasis in women with acute abnormal uterine bleeding, postpartum hemorrhage, and bleeding and clotting disorders including thrombotic microangiopathies.
  • Develop and disseminate a summary of what was discussed regarding the state-of-the- science in hemostatic disorders in women and girls and identify research gaps.
  • Effectively disseminate best practices in the care of women with abnormal uterine bleeding, hemophilia, postpartum hemorrhage, and thrombotic microangiopathies
  • Describe, and underscore for target healthcare providers, the intersection of obstetrics/gynecology and hematology in the optimal care of these women and develop mechanisms for facilitating the collaboration of these specialties

Click Here for the full meeting agenda. Register for this event through the HTRS registration portal.

Satellite Symposiums
Newly added as part of the virtual registration process, registrants will now be able to confirm their attendance for all sponsored virtual satellite sessions. Registration is complimentary for these events, and some offer Continuing Medical Education through the sponsor’s provider. Click here for the full meeting agenda.

Wednesday, March 10, 2021
12:00 PM - 1:00 PM ET

Pre-Symposium Satellite: Sanofi Genzyme

  • Session Title: "siRNA Technology in Hemophilia"
  • Speaker: Guy Young, MD, Director, Hemostasis and Thrombosis Program, Children's Hospital of LA; Professor of Pediatrics, Keck School of Medicine of USC
  • Overview: This presentation will cover small interfering RNA (siRNA) technology and its potential role in Hemophilia treatment.

Pre-Symposium Satellite: CSL Behring

  • Session Title: On-Demand Bleed Resolution in Hemophilia B With an Extended Half-Life Factor IX Therapy
  • Speaker: Miguel Escobar, MD; Professor, University of Texas Health Science Center at Houston-McGovern Medical School
  • Overview: This educational symposium will focus on the current role of Factor IX replacement therapy for on-demand resolution of bleeding episodes in patients with hemophilia B and will review the clinical trial data for on-demand use of IDELVION. Audience members will learn about the features of this product that made it an attractive choice in this setting. Attendees will hear about a case study of a patient who switched to IDELVION for on-demand therapy from a different FIX replacement product.

Wednesday, March 10, 2021
5:30 PM - 6:30 PM ET
Post-Symposium Satellite: Takeda

  • Session Title: ADVATE® [Antihemophilic Factor (Recombinant)] Clinical Presentation
  • Speaker: Dr Tammuella Chrisentery Singleton, MD, Chief, Pediatric Hematology, Director, Hemophilia Treatment Center, Mississippi Center for Advanced Medicine (MCAM), Louisiana Center for Advanced Medicine (LCAM)
  • Overview: ADVATE® [Antihemophilic Factor (Recombinant)] clinical information review through the lens of a patient case: Meet James (hypothetical patient, for illustrative purposes only)

Thursday, March 11, 2021
12:00 PM - 1:00 PM ET

Pre-Symposium Satellite: Novo Nordisk

  • Session Title: A rFVIIa with over 30 years of experience with treating hemophilia and other rare bleeding disorders
  • Speakers:
    • Stephanie Seremetis, MD, Chief Medical Officer, GD Biopharm, Novo Nordisk Inc.

    • Miguel Escobar, MD, Medical Director, Gulf States Hemophilia and Thrombophilia Center, University of Texas Health Science Center, Houston

    • Joanna Davis, MD, Medical Director, Pediatric Hemophilia Treatment Center, University of Miami Health System, Florida

  • Overview: Learn about the only rFVIIa approved for use in a wide range of indications in rare bleeding disorders including patients with congenital hemophilia with inhibitors of all ages, acquired hemophilia, Glanzmann's thrombasthenia, and congenital factor VII deficiency, through patient case reports.

Pre-Symposium Satellite: Bayer

  • Session Title: “Patient focused prophylaxis management for patients with hemophilia: a case-based discussion”
  • Speaker: Stacy Croteau, MD, MMS, Attending Physician, Boston Children’s Hospital, Medical Director, Boston Hemophilia Center, Assistant Professor of Pediatrics, Harvard Medical School
  • Overview: An interactive patient focused discussion on the importance of personalizing therapy with practical case studies based on real life clinical experience. The presentation will cover population PK models and available tools, benefits of integrating PK into hemophilia prophylaxis decision-making, how to generate PK profiles with population PK tools, and how provider and patient can best collaborate to set goals and decide on treatment plans.

Thursday, March 11, 2021
2:10 PM - 3:10 PM ET

Exclusive Satellite: Genentech

  • Session Title: SubQ Prophylaxis for Hemophilia A: 3 Experts Discuss the Latest Data From the Pivotal Trials 
  • Speakers
    • Amy Shapiro, MD, Indiana Hemophilia and Thrombosis Center, Inc.
    • Michael Callaghan, MD, Wayne State University School of Medicine Children's Hospital of Michigan
    • Guy Young, MD, University of Southern California Children's Hospital, Los Angeles
  • Overview: Join Drs. Amy Shapiro, Michael Callaghan, and Guy Young as they discuss subcutaneous prophylaxis for hemophilia A, their perceptions of the latest pivotal trial data, and how they have evolved their management of hemophilia A patients throughout the pandemic. This program will be presented live, with an opportunity to ask questions throughout the presentation. This promotional symposium is sponsored by Genentech, Inc.

Thursday, March 11, 2021
6:15 PM - 7:15 PM ET

Post-Symposium Satellite (CME): Takeda/PER

  • Session Title: Putting the Patient First: Individualized Strategies for the Treatment and Management of von Willebrand Disease
  • Speakers
    • Jonathan C. Roberts, MD, Associate Medical Director, Associate Research Director, Bleeding & Clotting Disorders Institute, Assistant Professor of Pediatrics, University of Illinois College of Medicine, Peoria, IL

    • Robert F. Sidonio, Jr., MD, MSc, Pediatric Hematologist, Medical Director of Hemophilia, Aflac Cancer & Blood Disorders Center, Children’s Healthcare of Atlanta, Associate Professor of Pediatrics, Emory University School of Medicine, Atlanta, GA

    • Angela C. Weyand, Assistant Professor of Pediatrics, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI

  • Overview: Although the clinical management of von Willebrand Disease (VWD) has evolved over the past few decades, it continues to pose a therapeutic challenge. There is currently no cure for VWD; however, there are safe and effective treatments for all known types of this disease. Ensuring that clinicians who treat this condition maintain knowledge that is at the forefront of clinical decision-making is critical to promoting optimized patient outcomes.

    This symposium features expert clinician-researcher faculty who will share data regarding the mechanistic activity, efficacy, and safety of therapeutic strategies that target VWD pathophysiology. Furthermore, the faculty will use in-depth, case-based discussion to share best practices for selecting therapy for patients with Type 1, 2, and 3 VWD.

Post-Symposium Satellite: Novo Nordisk

  • Session Title: Double Feature:  Obesity in Hemophilia and a Treatment Option for Hemophilia A
  • Speakers
    • Stephanie Seremetis, MD, Chief Medical Officer, GD Biopharm, Novo Nordisk Inc.

    • Meera B. Chitlur, MD, Professor of Pediatrics, Central Michigan University School of Medicine, Pediatric Hematologist/Oncologist, Children’s Hospital of Michigan

    • Doris Quon, MD, PhD, Medical Director, Orthopaedic Hemophilia Treatment Center, Orthopaedic Institute for Children, University of California, Los Angeles

    • Anthony Auriemma, MD, JD, Medical Director, The Center for Health and Nutrition

  • Overview: The first part is an interactive program discussing the importance of managing obesity in the hemophilia community.  Managing obesity is generally one of the toughest challenges for health care professionals and is often overlooked.  This program will feature a discussion on obesity as a disease and how obesity impacts people with hemophilia.  Results from a study designed to understand the barriers to initiating and maintaining weight loss in obese patients with hemophilia and to identify insights on the unique challenges of these patients from the perspective of health care professionals will be covered.

    In the second part, the program will feature aspects of the pathfinder clinical trial program and information on a factor VIII extended half-life product.

    The program is sponsored by Novo Nordisk and is being moderated by Dr. Stephanie Seremetis and will feature Dr. Meera Chitlur, Dr. Doris Quon and Dr. Anthony Auriemma.

Friday, March 12, 2021
12:00 PM - 1:00 PM ET

Pre-Symposium Satellite: Sanofi Genzyme

  • Session Title: "A Breakthrough in aTTP Treatment: Now recommended by the ISTH Guidelines"
  • Speaker: Dr. Jay Raval, Associate Professor and Senior Director of Transfusion Medicine and Therapeutic Pathology, University of New Mexico
  • Overview: The program will provide an overview of acquired thrombotic thrombocytopenic purpura (aTTP) – a rare, life-threatening, auto-immune disease - and the urgency for rapid diagnosis and treatment. The program will then review the recently published ISTH Guidelines on the diagnosis and treatment of aTTP with a focus on the first and only FDA-approved therapy indicated for adults with aTTP.

Pre-Symposium Satellite: Alnylam Pharmaceuticals

  • Session Title: Introduction to GIVLAARI® (givosiran) for the Treatment of Adults with Acute Hepatic Porphyria - Featuring 18-month data from the ENVISION Open-Label Extension (OLE) Study
  • Speaker: Dr. Appalanaidu Sasapu, MD
  • Overview: Join Alnylam Pharmaceuticals for a presentation featuring the latest information on GIVLAARI, an RNA interference (RNAi) therapeutic for the treatment of adults with Acute Hepatic Porphyria (AHP). AHP is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain. 

    GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP). GIVLAARI is contraindicated in patients with known severe hypersensitivity to givosiran. Reactions have included anaphylaxis. Additional Important Safety Information about GIVLAARI, including Contraindications, Warnings & Precautions for Anaphylactic Reaction, Hepatic Toxicity, and Injection Site Reactions can be found through these links to Important Safety Information and to the full Prescribing Information.

    Led by Dr. Appalanaidu Sasapu, this session will feature results from the 18-month analysis from the ENVISION ongoing open-label extension (OLE) study, as well as a range of topics including:
    •    AHP Disease overview and pathophysiology
    •    Introduction to GIVLAARI
    •    Mechanism of action for GIVLAARI
    •    Efficacy and safety results from the ENVISION study 

Register for all satellite symposiums are being collected through the HTRS registration portal. You must be pre-registered to participate. Registration will not close for these events, but for ease of access please register in advance.

Previously Registered?
Existing registrants received an email from about their registration payment and new options for the virtual conference. Participants who registered prior to the virtual relaunch may select one of the following options: 

  1. adjustment to current registration pricing and refund of the difference in cost
  2. maintain existing registration payment and donate the difference in costs to HTRS to put toward abstract awards, or
  3. request a full refund. 

If you did not receive this communication, please reach out to our Conference Management Team at for more information.

Cancellation Policy
If you must cancel your registration, all requests must be received in writing via email to and postmarked no later than February 15, 2021. All fees paid will be refunded minus a $50.00 processing fee. There will be no refunds after the February 15, 2021 deadline.

Special Needs Requests
If you need to request any special needs, such as translation services, closed captioning, other technical services, or have questions during the registration process, please contact

Connection Information
Our Conference Management Team will be distributing more information including connection information and login credentials for the mobile app and virtual platform  prior to the Symposium. This will allow attendees plenty of time to become familiar with the app, create their REMO account, explore e-posters, access sponsor/exhibitor information, and begin building their schedule for the week.

Code of Conduct
The HTRS Scientific Symposium is designed to increase engagement, collaboration, connectivity, and community, in a safe education environment. 

We value the participation of each member of the community and endeavor to deliver a fulfilling experience for all. Conference participants are expected to conduct themselves with integrity, courtesy, and respect for others and maintain the highest level of professionalism at all conference programs and events, whether officially sponsored by the HTRS or not. All attendees, speakers, organizers, volunteers, partners, vendors and staff at any HTRS event are required to observe the following Code of Conduct.

The HTRS is dedicated to providing a harassment-free conference experience for everyone, regardless of gender, sexual orientation, disability, physical appearance, body size, race or religion. We do not tolerate harassment of conference participants in any form. All communication should be appropriate for a professional audience including people of diverse backgrounds and cultures. Sexual language, imagery, and/or profanity are not appropriate at HTRS events.

Be kind to others. Do not insult or defame participants. Harassment in any form, sexist, racist, or exclusionary jokes are not condoned at the HTRS events. Not only are they not condoned, they will not be tolerated.

All presentations are the property of the presenter(s) sharing their knowledge with participants. Please do not pirate, capture, or download illegal presentations without the authorization of the presenter(s). Participants will have the ability to connect with the presenter(s) through the mobile app and are advised to contact the presenter directly if interested in receiving a copy of their presentation. All session recordings captured by HTRS during the event will be available for approximately one year post-conference. 

Dissemination of pertinent meeting information (weblinks, account passwords, etc.) is strictly prohibited.

Participants violating these rules may be asked to leave the conference at the sole discretion of the HTRS. 

Media Capture and Attribution
HTRS maintains the sole right to record, stream and host all content at HTRS events, whether in-person or virtually. Video and studio recording, including streaming of sessions for commercial use or outside of HTRS' virtual platform, is strictly prohibited. Recordings of all sessions will be hosted online by HTRS for at least one year following the event.

Presenters may share additional media and resources as part of their session or session record. These resources are provided for attendees’ personal use and are not for distribution unless the resource explicitly states that it can be broadly distributed or written permission is individually granted by the presenter. In either case, proper attribution to the original creator is required.

Photo Policy and Consent
By registering for the HTRS 2021 Scientific Symposium, you hereby consent to the use of your picture, portrait, or photograph, including video footage and the sound recording of your voice (collectively the "Photographs"), for advertising, marketing and promotional efforts, educational purposes, commercial purposes and any other legal purposes. The Photographs may be used in any format or media, including printed and electronic publication and Internet web pages. You understand the Photographs could be circulated worldwide and that there will be no compensation for this or any use. If you must decline the use of your likeness please email